Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALG.APV-527

Bispecific antibody · Immune activation, directed at 4-1BB (CD137) (TNFRSF9) and 5T4 (trophoblast glycoprotein) (TPBG) · developed by Aptevo Therapeutics

Phase 1/2 Most advanced trial (none active)

APVO Developer

1 Registered trials

What is ALG.APV-527?

ALG.APV-527 is a bispecific antibody in the ADAPTIR format with a silenced IgG1 Fc domain. It binds the co-stimulatory receptor 4-1BB on immune cells such as CD8+ T cells and natural killer cells, and the tumor-associated antigen 5T4. It is being studied in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Targets: 4-1BB (CD137) (TNFRSF9), 5T4 (trophoblast glycoprotein) (TPBG)
Mechanism: Immune activation, directed at 4-1BB (CD137) (TNFRSF9) and 5T4 (trophoblast glycoprotein) (TPBG)
Therapy area: Oncology
Developer: Aptevo Therapeutics (APVO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05934539	Phase 1/2	Solid Tumor	Unknown	APVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

Other drugs acting on TNFRSF9 / TPBG

Acasunlimab Phase 3 ADG106 Phase 1/2 ADG206 Phase 1 AGEN2373 Phase 1/2 CTX-471 Phase 1/2 Enristomig Phase 1 TUB-030 Phase 1/2

More from Aptevo Therapeutics

APVO210 Phase 1 ES414 Phase 1 Mipletamig Phase 1 Otlertuzumab Phase 1/2

Sources

ClinicalTrials.gov NCT05934539

Updated Oct 11, 2026. Something wrong or missing? Report it on the APVO page.

Follow APVO, the company behind ALG.APV-527

See APVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APVO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z